P966: SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM

• Gil Fridberg,
• Tamir Shragai,
• Natan Melamed,
• Svetlana Trestman,
• Iuliana Vaxman,
• Irit Avivi,
• Yael Cohen

Affiliations

Gil Fridberg

1 Tel Aviv Sourasky Medical Center and Sackler School of Medicine Tel Aviv University, Hematology, Tel Aviv, Israel

Tamir Shragai

2 Tel Aviv Sourasky Medical Center and Sackler School of Medicine Tel Aviv University, Hematology, Tel Aviv, Israel

Natan Melamed

3 Tel Aviv Sourasky Medical Center, Hematology, Tel Aviv, Israel

Svetlana Trestman

1 Tel Aviv Sourasky Medical Center and Sackler School of Medicine Tel Aviv University, Hematology, Tel Aviv, Israel

Iuliana Vaxman

4 Davidoff Cabcer Center, Rabin Medical Center and Sackler School of Medicine Tel Aviv University, Hematology, Petah Tikva, Israel

Irit Avivi

1 Tel Aviv Sourasky Medical Center and Sackler School of Medicine Tel Aviv University, Hematology, Tel Aviv, Israel

Yael Cohen

1 Tel Aviv Sourasky Medical Center and Sackler School of Medicine Tel Aviv University, Hematology, Tel Aviv, Israel